Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vipoma 1Somatostatinoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrinoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Paclitaxel 27Carboplatin 23Cisplatin 16Topotecan 8Taxes 8Docetaxel 7Gemcitabine 6Filgrastim 5Etoposide 4Doxorubicin 4Cyclophosphamide 4Psychiatric Rehabilitation 3Ifosfamide 3Chemotherapy, Adjuvant 3rubitecan 2pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Trabectedin 2Surgical Procedures, Operative 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Irinotecan 2GEN-1 2Fenretinide 2Erlotinib Hydrochloride 2Drug Therapy 2Celecoxib 2Bevacizumab 2Amifostine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Ovarian Neoplasms × motesanib diphosphate × Clear all
NCT00574951 2018-01-11

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Terminated
23 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡